Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Major AstraZeneca Shareholders Opposed to Share Bonus Hike for CEO

05/10/2021 | 05:06am EDT


© MT Newswires 2021
All news about ASTRAZENECA PLC
05:07pCureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy
RE
04:57pASTRAZENECA  : JPMorgan, Goldman Sachs delay workers' return to U.K. offices
RE
11:06aASTRAZENECA  : Second Phase of Covid-19 Vaccinations Begins
AQ
09:22aEU Says Johnson & Johnson May Not Meet Vaccine Supply Commitment After Jabs C..
MT
07:49aUK Vaccination Rate Slows Down On Shortage Of Pfizer Jabs
MT
04:08aER+/ HER2-VE BREAST CANCER PIPELINE : Emerging Therapies and Key pharma players ..
AQ
01:30aASTRAZENECA  : COVID-19 Approved In Pakistan For People Under 40
MT
06/15US, EU Vow to Provide COVID-19 Vaccine to Two-Thirds of World's Population by..
MT
06/15INDIAN SCIENTISTS : We didn't back doubling of vaccine dosing gap
RE
06/15European Stocks End Higher as Investors Wait for Fed
MT
More news
Financials (USD)
Sales 2021 30 989 M - -
Net income 2021 4 562 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 24,2x
Yield 2021 3,39%
Capitalization 110 B 156 B -
EV / Sales 2021 3,91x
EV / Sales 2022 3,41x
Nbr of Employees 76 100
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 132,31 $
Last Close Price 84,04 $
Spread / Highest target 103%
Spread / Average Target 57,4%
Spread / Lowest Target 14,5%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC13.91%154 316
JOHNSON & JOHNSON4.52%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.7.55%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.8.10%204 582